18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer

US10016519B2 · kind B2 · utility

Assignees

• Deutsches Krebsforschungszentrum · DE
• RUPRECHT - KARLS - UNIVERSITÄT HEIDELBERG · DE

Inventors

• Klaus Kopka · Dossenheim, DE
• Martina Benesova · Neckarsteinach, DE
• Jens Cardinale · Wien, AT
• Matthias Eder · Freiburg (Elbe), DE
• Martin SCHÄFER · Neckarsteinach, DE
• Ulrike BAUDER-WÜST · Schriesheim, DE
• Uwe Haberkorn · Schwetzingen, DE
• Michael Eisenhut · Heidelberg, DE

Key dates

• Filing date: Mar 20, 2017
• Grant date: Jul 10, 2018
• Expiry date: Mar 20, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/05
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer.